IAP
EBS icon

Indie Asset Partners’s Emergent Biosolutions EBS Stock Holding History

Indie Asset Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,300
Closed -$208K – 128
2021
Q2 		$208K Sell
3,300
-225
-6% -$14.5K 0.17% 117
2021
Q1 		$328K Buy
3,525
+200
+6% +$20.5K 0.37% 74
2020
Q4 		$298K Buy
+3,325
New +$305K 0.35% 72

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Indie Asset Partners's EBS Position: Q3 2021 in Review

Indie Asset Partners sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 3,300 shares — an estimated $208K sold.

Indie Asset Partners first reported a position in EBS in Q4 2020 and held it in 3 quarters. The position peaked at $328K in Q1 2021. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

  • Indie Asset Partners reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
  • Indie Asset Partners sold 3,300 Emergent Biosolutions shares in Q3 2021, an estimated $208K.
  • Indie Asset Partners first reported a position in Emergent Biosolutions in Q4 2020 and held it in 3 quarters.
  • Indie Asset Partners's Emergent Biosolutions position peaked at $328K in Q1 2021.
  • 277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Indie Asset Partners's 13F filing for Q3 2021, filed 9 Nov 2021.